Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of GS-9674 in NASH
2016-002496-10Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing GS-9674 with Placebo (2 arms). Primary endpoint: Safety of GS-9674. Started Dec 2016; status: completed.
02
Drugs
cilofexor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2016-002496-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002496-10.